FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138355864> ?p ?o ?g. }

• W2138355864 endingPage "1207" @default.
• W2138355864 startingPage "1198" @default.
• W2138355864 abstract "Some patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocorticoids.In this randomized, double-blind, double-dummy study, we assigned 576 patients with recurrent asthma exacerbations and evidence of eosinophilic inflammation despite high doses of inhaled glucocorticoids to one of three study groups. Patients were assigned to receive mepolizumab, a humanized monoclonal antibody against interleukin-5, which was administered as either a 75-mg intravenous dose or a 100-mg subcutaneous dose, or placebo every 4 weeks for 32 weeks. The primary outcome was the rate of exacerbations. Other outcomes included the forced expiratory volume in 1 second (FEV1) and scores on the St. George's Respiratory Questionnaire (SGRQ) and the 5-item Asthma Control Questionnaire (ACQ-5). Safety was also assessed.The rate of exacerbations was reduced by 47% (95% confidence interval [CI], 29 to 61) among patients receiving intravenous mepolizumab and by 53% (95% CI, 37 to 65) among those receiving subcutaneous mepolizumab, as compared with those receiving placebo (P<0.001 for both comparisons). Exacerbations necessitating an emergency department visit or hospitalization were reduced by 32% in the group receiving intravenous mepolizumab and by 61% in the group receiving subcutaneous mepolizumab. At week 32, the mean increase from baseline in FEV1 was 100 ml greater in patients receiving intravenous mepolizumab than in those receiving placebo (P=0.02) and 98 ml greater in patients receiving subcutaneous mepolizumab than in those receiving placebo (P=0.03). The improvement from baseline in the SGRQ score was 6.4 points and 7.0 points greater in the intravenous and subcutaneous mepolizumab groups, respectively, than in the placebo group (minimal clinically important change, 4 points), and the improvement in the ACQ-5 score was 0.42 points and 0.44 points greater in the two mepolizumab groups, respectively, than in the placebo group (minimal clinically important change, 0.5 points) (P<0.001 for all comparisons). The safety profile of mepolizumab was similar to that of placebo.Mepolizumab administered either intravenously or subcutaneously significantly reduced asthma exacerbations and was associated with improvements in markers of asthma control. (Funded by GlaxoSmithKline; MENSA ClinicalTrials.gov number, NCT01691521.)." @default.
• W2138355864 created "2016-06-24" @default.
• W2138355864 creator A5005167055 @default.
• W2138355864 creator A5011255987 @default.
• W2138355864 creator A5034252128 @default.
• W2138355864 creator A5035835345 @default.
• W2138355864 creator A5056919832 @default.
• W2138355864 creator A5058416167 @default.
• W2138355864 creator A5073019940 @default.
• W2138355864 creator A5073547325 @default.
• W2138355864 creator A5076439834 @default.
• W2138355864 creator A5082059107 @default.
• W2138355864 creator A5083168040 @default.
• W2138355864 date "2014-09-25" @default.
• W2138355864 modified "2023-10-10" @default.
• W2138355864 title "Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma" @default.
• W2138355864 cites W1970648068 @default.
• W2138355864 cites W1975915837 @default.
• W2138355864 cites W1988758075 @default.
• W2138355864 cites W1994585625 @default.
• W2138355864 cites W2000650705 @default.
• W2138355864 cites W2006174105 @default.
• W2138355864 cites W2013105339 @default.
• W2138355864 cites W2026670696 @default.
• W2138355864 cites W2035632341 @default.
• W2138355864 cites W2057490898 @default.
• W2138355864 cites W2060497576 @default.
• W2138355864 cites W2062918919 @default.
• W2138355864 cites W2068966334 @default.
• W2138355864 cites W2075699130 @default.
• W2138355864 cites W2095754126 @default.
• W2138355864 cites W2096018298 @default.
• W2138355864 cites W2098276532 @default.
• W2138355864 cites W2118939220 @default.
• W2138355864 cites W2155144195 @default.
• W2138355864 cites W2601675613 @default.
• W2138355864 doi "https://doi.org/10.1056/nejmoa1403290" @default.
• W2138355864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25199059" @default.
• W2138355864 hasPublicationYear "2014" @default.
• W2138355864 type Work @default.
• W2138355864 sameAs 2138355864 @default.
• W2138355864 citedByCount "1688" @default.
• W2138355864 countsByYear W21383558642014 @default.
• W2138355864 countsByYear W21383558642015 @default.
• W2138355864 countsByYear W21383558642016 @default.
• W2138355864 countsByYear W21383558642017 @default.
• W2138355864 countsByYear W21383558642018 @default.
• W2138355864 countsByYear W21383558642019 @default.
• W2138355864 countsByYear W21383558642020 @default.
• W2138355864 countsByYear W21383558642021 @default.
• W2138355864 countsByYear W21383558642022 @default.
• W2138355864 countsByYear W21383558642023 @default.
• W2138355864 crossrefType "journal-article" @default.
• W2138355864 hasAuthorship W2138355864A5005167055 @default.
• W2138355864 hasAuthorship W2138355864A5011255987 @default.
• W2138355864 hasAuthorship W2138355864A5034252128 @default.
• W2138355864 hasAuthorship W2138355864A5035835345 @default.
• W2138355864 hasAuthorship W2138355864A5056919832 @default.
• W2138355864 hasAuthorship W2138355864A5058416167 @default.
• W2138355864 hasAuthorship W2138355864A5073019940 @default.
• W2138355864 hasAuthorship W2138355864A5073547325 @default.
• W2138355864 hasAuthorship W2138355864A5076439834 @default.
• W2138355864 hasAuthorship W2138355864A5082059107 @default.
• W2138355864 hasAuthorship W2138355864A5083168040 @default.
• W2138355864 hasBestOaLocation W21383558641 @default.
• W2138355864 hasConcept C126322002 @default.
• W2138355864 hasConcept C142724271 @default.
• W2138355864 hasConcept C168563851 @default.
• W2138355864 hasConcept C204787440 @default.
• W2138355864 hasConcept C27081682 @default.
• W2138355864 hasConcept C2776042228 @default.
• W2138355864 hasConcept C2777037409 @default.
• W2138355864 hasConcept C2777832160 @default.
• W2138355864 hasConcept C42219234 @default.
• W2138355864 hasConcept C44249647 @default.
• W2138355864 hasConcept C71924100 @default.
• W2138355864 hasConceptScore W2138355864C126322002 @default.
• W2138355864 hasConceptScore W2138355864C142724271 @default.
• W2138355864 hasConceptScore W2138355864C168563851 @default.
• W2138355864 hasConceptScore W2138355864C204787440 @default.
• W2138355864 hasConceptScore W2138355864C27081682 @default.
• W2138355864 hasConceptScore W2138355864C2776042228 @default.
• W2138355864 hasConceptScore W2138355864C2777037409 @default.
• W2138355864 hasConceptScore W2138355864C2777832160 @default.
• W2138355864 hasConceptScore W2138355864C42219234 @default.
• W2138355864 hasConceptScore W2138355864C44249647 @default.
• W2138355864 hasConceptScore W2138355864C71924100 @default.
• W2138355864 hasIssue "13" @default.
• W2138355864 hasLocation W21383558641 @default.
• W2138355864 hasLocation W21383558642 @default.
• W2138355864 hasLocation W21383558643 @default.
• W2138355864 hasOpenAccess W2138355864 @default.
• W2138355864 hasPrimaryLocation W21383558641 @default.
• W2138355864 hasRelatedWork W2002613275 @default.
• W2138355864 hasRelatedWork W2013851350 @default.
• W2138355864 hasRelatedWork W2995082828 @default.
• W2138355864 hasRelatedWork W3159250744 @default.
• W2138355864 hasRelatedWork W4233016836 @default.

• next